- Home
- FRMI vs PCVX Comparison
FRMI vs PCVX Comparison
Compare FRMI & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FRMI | PCVX |
|---|---|---|
| Founded | 2025 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.0B | 6.1B |
| IPO Year | 2025 | 2020 |
Fundamental Metrics
Financial Performance| Metric | FRMI | PCVX |
|---|---|---|
| Price | $9.19 | $53.76 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 7 |
| Target Price | $30.86 | ★ $105.00 |
| AVG Volume (30 Days) | ★ 6.9M | 991.0K |
| Earning Date | 05-12-2026 | 02-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.28 | $27.66 |
| 52 Week High | $36.99 | $93.77 |
Technical Indicators
Market Signals| Indicator | FRMI | PCVX |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 69.82 |
| Support Level | N/A | $44.85 |
| Resistance Level | N/A | $48.93 |
| Average True Range (ATR) | 0.00 | 2.58 |
| MACD | 0.00 | 0.59 |
| Stochastic Oscillator | 0.00 | 89.59 |
Price Performance
Historical ComparisonAbout FRMI Fermi Inc.
Fermi Inc is an energy and hyperscaler development company purpose-built for the AI era. Its Project Matador, a multi-gigawatt energy and data center development campus designed to support the accelerating needs of to-be-built AI infrastructure. Through its REIT structure, Fermi offers investors exposure to AI infrastructure growth and long-term, large-scale and reliable energy development in a tax-efficient public vehicle.
About PCVX Vaxcyte Inc.
Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.